Insight Molecular Diagnostics Inc. (IMDX)
Nasdaq · Healthcare · Diagnostics & Research
$3.67+6.69%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $120M
- 52-week range
- $2.42 – $8.51
- 52-week change
- −6.52%
- EPS (trailing)
- −$1.52
- Analyst rating
- 2.0 Buy
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Revenue
- $4.1M (+115.58%)
- Net income
- −$50K
- Operating margin
- −1260.8%
- Diluted EPS
- −$1.65
- Free cash flow
- −$25.4M
From the company’s annual report on SEC EDGAR.
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests.
Headquarters: Nashville, United States · 55 employees · imdxinc.com